Ashleigh and her team assisted with IRC 409A / ASC 718 valuation needs for Tyra Biosciences, a clinical stage biotechnology company.

The team started working with the company after its first round of funding, a Series A tranched financing. The company then raised a Series B and began prepping to go public.

During this time, the team completed multiple engagements as the company considered two possible IPO paths: a near-term and delayed offering. The company moved quickly on its public offering path, and the team completed four valuations within a six-month period leading up to the public offering. The team ensured timely delivery of complex analyses so the company could continue granting stock options in the months leading up to going public and have accurate stock-based compensation expense in its SEC filings.

Tyra Biosciences successfully went public on September 17, 2021.

Note: This work was performed prior to joining Stout.